Is tirzepatide legal? EU, UK and US status

Tirzepatide is a prescription medicine in every jurisdiction that has reviewed it. The short answer to 'is tirzepatide legal?' is: yes, within a licensed healthcare system, and no, outside one. In the United States, the FDA approved tirzepatide as Mounjaro for type-2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023^[2]. The EMA authorised it across the EU and EEA as Mounjaro for both indications in September 2022^[1]. In the UK, the MHRA licensed it and NICE has issued two separate technology appraisals governing NHS access^[3]. What is not legal, in any of these jurisdictions, is selling, purchasing, or importing tirzepatide outside a regulated supply chain.

This page is for educational and journalistic purposes only and does not constitute legal or medical advice. Regulations can change. Verify current status with the official regulator in your country before making any decision. PeptideMethods.com is not a law firm.

Tirzepatide in the United States

The FDA approved Mounjaro (tirzepatide injection) in May 2022 as an adjunct to diet and exercise to improve glycaemic control in adults and, following a label update, in paediatric patients aged 10 and over with type-2 diabetes^[2]. The label carries a boxed warning: tirzepatide causes thyroid C-cell tumours in rats, and human relevance is undetermined. Medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 are contraindications.

In November 2023 the FDA approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 or above) or with overweight (BMI of 27 or above) plus at least one weight-related comorbidity. The molecule, dose strengths, and injection schedule are identical to Mounjaro; the brand split reflects the different indication and commercial positioning, not a different formulation.

During a period of documented shortage in 2022 and 2023, US compounding pharmacies could legally prepare tirzepatide under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Once the FDA declared the shortage resolved, large-scale compounding of tirzepatide was no longer permitted under enforcement discretion. 'Research-use only' vials of tirzepatide sold online are not authorised human medicines, regardless of how they are labelled.

The US also has a separate OSA indication. In December 2024 the FDA expanded the Zepbound label to cover moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial data. That indication does not exist under the Mounjaro brand and is not available in the EU or UK as of this writing.

Tirzepatide in the European Union

The EMA granted Mounjaro a centralised marketing authorisation on 15 September 2022^[1]. That single authorisation applies across all EU member states and EEA countries. The EMA's indication covers type-2 diabetes in adults as an adjunct to diet and exercise, and weight management in adults with obesity or overweight plus a weight-related comorbidity.

Within those broad EMA parameters, individual member states set their own reimbursement decisions. Germany, France, Denmark, Sweden, the Netherlands, and other EU jurisdictions each run their own health technology assessment processes. The EMA authorisation establishes that tirzepatide can be prescribed; national reimbursement bodies decide whether public health insurance covers the cost. In practice, coverage for weight management is more restricted than for type-2 diabetes in several EU countries, because the obesity indication arrived later and the cost-effectiveness assessments are still being completed by some national agencies.

Tirzepatide is classified as a prescription-only medicine throughout the EU. Purchasing it without a prescription from a licensed prescriber, or importing it through non-regulated channels, falls outside the legal framework in every member state. EU medicines law makes it an offence to supply an unauthorised medicine or to supply a prescription-only medicine without a valid prescription, and these rules apply to online pharmacies operating within the EU as well as to vendors operating from outside it.

Tirzepatide in the United Kingdom

The MHRA licensed Mounjaro in the UK for both type-2 diabetes and weight management, following a review independent of the EMA post-Brexit. NHS access is governed by NICE, which has issued two separate technology appraisals. NICE TA924, published in October 2023, covers tirzepatide as a treatment option for type-2 diabetes^[3]. NICE TA1026, published in December 2024, covers tirzepatide for managing overweight and obesity within specialist weight-management services^[4].

The two NICE appraisals have different eligibility criteria and route patients through different clinical settings. TA924 targets patients with type-2 diabetes who have not achieved adequate glycaemic control on existing therapy, typically after at least two prior oral agents. TA1026 applies to specialist NHS weight-management services and uses BMI and comorbidity thresholds tighter than the MHRA marketing authorisation alone. Eligibility under one TA does not transfer to the other, and the clinical pathway is different in each case.

Private prescription is a legal route for patients who fall outside NHS criteria. UK private pharmacies can dispense Mounjaro against a valid private prescription from a licensed UK prescriber. Private pricing varies by pharmacy and dose strength, and patients should verify costs directly before assuming any quoted figure. Importing tirzepatide from outside the UK without a prescription, or buying it through unregulated online sources, is not within the law and may expose buyers to products that are counterfeit, mislabelled, or of unknown purity.

What grey-market tirzepatide actually is

A grey market in 'research-grade' tirzepatide exists online, with products sold as vials for 'laboratory use only.' These are not the same as the branded Mounjaro or Zepbound pens. The branded products are manufactured to pharmaceutical-grade standards under Good Manufacturing Practice and carry full regulatory dossiers. Vials sold outside the regulated supply chain have no such guarantee. Purity, concentration, and sterility are all unknown without independent testing. Additionally, the clinical-trial data on efficacy and safety, including the SURMOUNT-1 finding of 20.9% mean body-weight reduction at 72 weeks on 15 mg weekly^[5], applies to the pharmaceutical formulation trialled, not to any compounded or grey-market alternative.

Regulators have responded. In the US, the FDA sent warning letters to compounding pharmacies producing tirzepatide after the shortage was resolved. In the EU, Directive 2001/83/EC and the EU Falsified Medicines Directive make it an offence to supply or possess with intent to supply an unauthorised medicinal product. In the UK, the Human Medicines Regulations 2012 apply the same principle. The 'research use only' label does not create a legal exemption for human consumption in any of these jurisdictions.

What is not settled

Paediatric obesity approvals are an open area. The EMA has a paediatric investigation plan registered for tirzepatide, and the December 2025 CHMP positive opinion extended the EU diabetes label to children aged 10 and over, but a paediatric obesity authorisation has not yet been issued in the EU, UK, or US. The OSA indication approved in the US for Zepbound in December 2024 has not been assessed by NICE in the UK or by the EMA for the EU. The reimbursement landscape is also still settling: access criteria differ by country and by service pathway within countries, and will change as health technology assessments are updated.

Where this leaves readers

If you are considering tirzepatide, the legal and medically appropriate route runs through a licensed prescriber in your country. See tirzepatide regulation by country for per-jurisdiction detail, and the tirzepatide peptide page for the full clinical and safety picture. For UK NHS access specifically, the NICE TA924 and TA1026 routes are covered in detail in our UK access explainer.

Always consult a qualified healthcare provider before starting or stopping any medicine. If you have legal questions about prescription status in your specific country, consult a lawyer or your national medicines regulator directly.